Huijie Wang

ORCID: 0000-0002-1451-5158
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Periodontal Regeneration and Treatments
  • Metastasis and carcinoma case studies
  • Hematopoietic Stem Cell Transplantation
  • Muscle Physiology and Disorders
  • Crystal structures of chemical compounds
  • Telomeres, Telomerase, and Senescence
  • Rheology and Fluid Dynamics Studies
  • Cancer Immunotherapy and Biomarkers
  • Dental Implant Techniques and Outcomes
  • Heat Transfer and Optimization
  • Chromatin Remodeling and Cancer
  • Peptidase Inhibition and Analysis
  • PI3K/AKT/mTOR signaling in cancer
  • Mycorrhizal Fungi and Plant Interactions
  • Immune Cell Function and Interaction
  • Polymer Foaming and Composites
  • Fungal Biology and Applications
  • Cancer Genomics and Diagnostics

Heilongjiang Bayi Agricultural University
2025

Fudan University Shanghai Cancer Center
2014-2024

Henan Institute of Science and Technology
2023

Shanghai Medical College of Fudan University
2014-2021

Xuzhou Medical College
2019

Luoyang Central Hospital Affiliated to Zhengzhou University
2009-2018

Université de Montréal
2017

Zhengzhou University
2016

Fudan University
2014

Institute for Animal Husbandry
2007

Skeletal muscle is an essential tissue for maintaining the body's basic functions. The structural unit of skeletal fiber, and its type main factor that determines athletic ability animals. O-linked N-acetylglucosamine (O-GlcNAc) modification, a reversible protein post-translational involved in many important biological processes such as gene transcription, signal transduction, cell growth, differentiation. Myogenic differentiation (MyoD), first discovered myogenic regulatory factor,...

10.1016/j.jbc.2025.108364 article EN cc-by-nc-nd Journal of Biological Chemistry 2025-02-01

Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase ( ALK )‐positive non‐small cell lung cancer (NSCLC). Herein, we reported the updated data on overall survival (OS) and molecular profiling from study. Methods In this study, 180 received 225 mg of orally once daily until disease progression, death or withdrawal. OS was estimated by Kaplan‒Meier...

10.1002/cac2.12524 article EN cc-by-nc-nd Cancer Communications 2024-02-29

Impaired T cell reconstitution remains a major deterrent in the field of bone marrow (BM) transplantation (BMT) due to pre-conditioning-induced damages inflicted thymi recipient hosts. Given previously reported thymo-stimulatory property interleukin (IL)-21, we reasoned that its use post-BMT could have profound effect on de novo development. To evaluate IL-21 development vivo, BM derived from RAG2p-GFP mice was transplanted into LP/J mice. Lymphocyte first assessed using hematological...

10.1186/s13045-017-0490-3 article EN cc-by Journal of Hematology & Oncology 2017-06-14

Background and Purpose Cancer cachexia cancer‐associated thrombosis are potentially fatal outcomes of advanced cancer. Nevertheless, thrombin expression in non‐small cell lung cancer (NSCLC) primary tumour tissues the association between prognosis NSCLC patients remain largely unknown. Experimental Approach Clinical pathological analysis was performed to determine relationship progression. Effects r‐hirudin direct inhibitor peptide (DTIP) on progression were evaluated. Western blotting,...

10.1111/bph.15384 article EN British Journal of Pharmacology 2021-01-23

Current pemetrexed/platinum chemotherapy does not produce a satisfactory therapeutic response in advanced lung cancer patients. The aim of this study was to determine whether the administration gefitinib, tyrosine kinase inhibitor (TKI), intercalated with could improve efficacy chemotherapy-naïve patients non-squamous NSCLC without subsequent gefitinib maintenance therapy. Treatment-naïve stage IIIB or IV were randomly assigned receive pemetrexed (500 mg/m2 d1) and either cisplatin (75...

10.4161/cbt.28874 article EN Cancer Biology & Therapy 2014-04-22

The aim of this study was to investigate the association telomere length with breast cancer risk. We simultaneously explored between telomerase reverse transcriptase gene polymorphisms and length.We used real-time quantitative polymerase chain reaction measure relative (RTL) in genomic DNA extracted from peripheral blood 183 cases 191 healthy controls. Genotyping performed using Sequenom MassARRAY platform.Our results show that patients had significantly shorter RTLs than control subjects...

10.4048/jbc.2018.21.e52 article EN cc-by-nc Journal of Breast Cancer 2018-01-01

Previous studies showed an association between the ZNF208 gene and gastric cancer. In this study, we investigated single nucleotide polymorphisms (SNPs) in risk of esophageal cancer a Chinese Han population. We conducted case-control study that included 386 cases 495 controls. Five SNPs were selected from previous genome-wide genotyped using Sequenom MassARRAY platform. Unconditional logistic regression was used to calculate odds ratios 95% confidence intervals after adjustment for age...

10.18632/oncotarget.13468 article EN Oncotarget 2016-11-19

<sec> <b>Objective</b> The aim of this trial was to compare both the efficacy and safety a weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus cisplatin <i>vs.</i> gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). </sec> <b>Methods</b> A total 84 participants received either 100 mg/m<sup>2</sup> nab-paclitaxel each week on d 1, 8 15 28 day cycle, as well 75 1 every three weeks (nab-TP arm); or 1,000 8, (GP arm). primary end point progression-free...

10.21147/j.issn.1000-9604.2019.02.08 article EN Chinese Journal of Cancer Research 2019-01-01

// Xinmin Zhao 1, * , Hui Yu Jing 2 Xianghua Wu 1 Si Sun Zhiguo Luo Huijie Wang Jie Qiao Jianhua Chang and Jialei Department of Medical Oncology, Fudan University Shanghai Cancer Center, College, University, 200032, China Pulmonary Hospital Affiliated to Tongji School Institute, 200433, These authors have contributed equally this work Correspondence to: Wang, email: m18017312369@163.com Chang, changjianhua@163.com Keywords: non-small-cell lung cancer, pemetrexed, carboplatin, elderly,...

10.18632/oncotarget.21186 article EN Oncotarget 2017-09-23

The addition of bevacizumab or pembrolizumab to pemetrexed-platinum chemotherapy has produced significant clinical benefits patients with untreated, advanced non-squamous non-small cell lung cancer (NSCLC) lacking targetable genetic aberrations. However, the direct comparison between these two first-line treatments needs be investigated.We retrospectively investigated medical records 102 stage IIIB~IV NSCLC, and without sensitizing EGFR/ALK/ROS1 alterations. All received plus as treatment...

10.3389/fonc.2021.752545 article EN cc-by Frontiers in Oncology 2021-09-29

In order to explore the application of precision extracoronal attachment based on three-dimensional finite element stress model in repair unilateral mandibular dissociation and loss, distribution butment periodontal tissues when was used loss analyzed, so as provide reference for materials clinical repair. this study, biomechanics oral cavity its were analyzed theoretical basis construction. Because degree tissue absorption number abutment teeth affected restoration effect coronal...

10.1016/j.sjbs.2019.09.022 article EN cc-by-nc-nd Saudi Journal of Biological Sciences 2019-09-24

Six Cd(II)/Mn(II)/Co(II)/Ni(II)/Zn(II) coordination complexes are formulated as [Cd2(X2−)2(μ3-O)2/3]n (1), [Mn2(X2−)2(μ3-O)2/3]n (2), {[Co1.5(Y4−)0.5(4,4′-bpy)1.5(OH−)]·2H2O}n (3), {[Ni(X2−)(4,4′-bpy)(H2O)2]·4H2O}n (4), [Zn(m-bdc2−)(bebiyh)]n (5), and [Cd(5-tbia2−)(bebiyh)]n (6) (H2X = 3,3′-(2,3,5,6-tetramethyl-1,4-phenylene) dipropionic acid. H4Y 2,2′-(2,3,5,6-tetramethyl-1,4-phenylene)bis(methylene) dimalonic acid, bebiyh 1,6-bis(2-ethyl-1H-benzo[d]imidazol-1-yl)hexane, m-H2bdc...

10.3390/polym15071803 article EN Polymers 2023-04-06

e21074 Background: SMARCA4-deficient thoracic sarcomatoid tumors (SD-TSTs) is a rare and highly aggressive disease that lack clear treatment guidelines. This research reports the clinicopathological features of SD-TSTs promising efficacy immune-checkpoint inhibitor with chemotherapy in SD-TSTs. Methods: A total 16 patients were diagnosed treated Fudan University Shanghai Cancer Center (FUSCC) from January, 2017 to December, 2021. Clinicopathologic, genomic characteristics information...

10.1200/jco.2022.40.16_suppl.e21074 article EN Journal of Clinical Oncology 2022-06-01
Coming Soon ...